GeneDx is trading at $66.32 (4.4% down) today, likely influenced by a series of recent class action lawsuit alerts against the company. These lawsuits, with fresh alerts issued as recently as July 10, 2026, stem from the company's Q1 2026 results and a significant impairment charge related to its Fabric Genomics acquisition, which caused a substantial stock decline in May 2026. No new company-specific filings or guidance changes dated July 10, 2026, directly explain today's decline.